Astria Therapeutics, Inc. (ATXS)

9,64 -0,16 (-1,63%) Al cierre: 04:00PM EDT

Astria Therapeutics, Inc.

75 State Street
Suite 1400
Boston, MA 02109
United States
617 349 1971
https://www.astriatx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 59

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Ms. Jill C. Milne Ph.D.	Co-Founder, CEO, President & Director	928,52k	N/A	1968
Mr. Benjamin S. Harshbarger J.D.	Chief Legal Officer	621,91k	N/A	1969
Mr. Noah C. Clauser CPA	CFO & Treasurer	508,79k	N/A	1974
Ms. Keri McGrail	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Andrew A. Komjathy	Chief Commercial Officer	N/A	N/A	1964
Dr. Christopher J. Morabito M.D.	Chief Medical Officer	N/A	N/A	1971
Mr. John Ruesch	Senior Vice President of Pharmaceutical Sciences & Technical Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Astria Therapeutics, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 5; Tablero: 7; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.